Litcius/Paper detail

Glucose variability as the risk factor of preeclampsia in pregnant patients with type 1 diabetes mellitus

A. V. Tiselko, Roman V. Kapustin, Yu. P. Milyutina, Natalia V. Borovik, Elena I. Abashova, Maria I. Yarmolinskaya

2022The Journal of Maternal-Fetal & Neonatal Medicine14 citationsDOI

Abstract

OBJECTIVE: To analyze glucose variability and investigate its role as a predictor for preeclampsia development in pregnant women with type 1 diabetes mellitus (T1DM) with various insulin therapy regimens. METHODS: A total of 200 pregnant women with T1DM were included in the study. A hundred women used continuous subcutaneous insulin infusion (CSII), and the rest of the group was administered with multiple daily insulin injections (MDI). Continuous glucose monitoring (CGM), index calculation of glucose variability (MAGE, MODD, CONGA, and CV), assessment of preeclampsia frequency and severity were conducted. RESULTS: < .001). The increase of risk of preeclampsia development is proved in pregnant patients with T1DM when the hyperglycemic condition lasts more than 25% of a 24-h period according to the rate of CGM and measurements of glucose variability MODD > 1.07 and CONGA > 3.39. CONCLUSION: Comprehensive evaluation of the glycemic profile while using CGM revealed a correlation between pathological glucose variability and the frequency and severity of preeclampsia thus proving the benefits of CSII in pregnant patients with T1DM to perform glycemic targets and decrease glucose variability, which eventually led to the decrease of preeclampsia frequency in this group of women.

Topics & Concepts

PreeclampsiaMedicinePregnancyObstetricsDiabetes mellitusType 1 diabetesGestational diabetesType 2 Diabetes MellitusInternal medicineGestational ageGestationEndocrinologyBiologyGeneticsGestational Diabetes Research and ManagementPregnancy and preeclampsia studiesDiabetes Management and Research